Circulating levels of vasoactive intestinal polypeptide in liver disease
- 1 September 1979
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 139 (9), 994-996
- https://doi.org/10.1001/archinte.139.9.994
Abstract
In animals, the effects of vasoactive intestinal polypeptide (VIP) include peripheral vasodilation, hyperdynamic circulation, hyperglycemia and hyperventilation. Because these phenomena are noted in patients with cirrhosis, it has been postulated that VIP might be escaping hepatic inactivation and entering the systemic circulatory system and contributing to these abnormalities. VIP levels were studied in patients with cirrhosis, acute liver disease and chronic illnesses with secondary liver involvement. Patients with cirrhosis and those with acute liver disease or chronic illnesses with secondary hepatic involvement have a wide range of VIP levels with mean values significantly above that of normal individuals and patients with chronic illness and no liver involvement.This publication has 6 references indexed in Scilit:
- Vasoactive Intestinal Polypeptide Occurs in Nerves of the Female Genitourinary TractScience, 1977
- Vasoactive intestinal polypeptide in brain: localization in and release from isolated nerve terminals.Proceedings of the National Academy of Sciences of the United States of America, 1977
- Vasoactive intestinal peptide (VIP) cells in the pancreas and gastro-intestinal mucosaHistochemistry and Cell Biology, 1977
- Vasoactive Intestinal Polypeptide: Abundant Immunoreactivity in Neural Cell Lines and Normal Nervous TissueScience, 1976
- POSSIBLE DUAL ROLE FOR VASOACTIVE INTESTINAL PEPTIDE AS GASTROINTESTINAL HORMONE AND NEUROTRANSMITTER SUBSTANCEThe Lancet, 1976
- Radioimmunoassay of vasoactive intestinal peptideJournal of Surgical Research, 1976